Thalidomide has shown efficacy in the treatment of advanced refractory multiple myeloma even after autologous stem-cell transplantation  and has been evaluated alone or in combination in the treatment of various solid and hematological malignancies [2–4]. Both antiangiogenic activity  and the immunomodulatory properties of thalidomide are proposed mechanisms for its beneficial effects . Common side-effects during treatment with thalidomide are sedation, constipation, skin rash and peripheral neuropathy. Less frequently bradycardia, hypotension and hypothyroidism have been described . However, life-threatening toxicity due to thalidomide has occurred as toxic epidermal necrolysis , and in combination with steroids or anthracycline-based chemotherapy an increased incidence of thromboembolic events has been observed .